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Predicting COPD 1-year mortality using
prognostic predictors routinely measured in
primary care
C. I. Bloom1*†, F. Ricciardi2†, L. Smeeth3, P. Stone4 and J. K. Quint5
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a major cause of mortality. Patients with advanced
disease often have a poor quality of life, such that guidelines recommend providing palliative care in their last year
of life. Uptake and use of palliative care in advanced COPD is low; difficulty in predicting 1-year mortality is thought
to be a major contributing factor.
Methods: We identified two primary care COPD cohorts using UK electronic healthcare records (Clinical Practice
Research Datalink). The first cohort was randomised equally into training and test sets. An external dataset was
drawn from a second cohort. A risk model to predict mortality within 12 months was derived from the training set
using backwards elimination Cox regression. The model was given the acronym BARC based on putative prognostic
factors including body mass index and blood results (B), age (A), respiratory variables (airflow obstruction, exacerbations,
smoking) (R) and comorbidities (C). The BARC index predictive performance was validated in the test set and external
dataset by assessing calibration and discrimination. The observed and expected probabilities of death were assessed for
increasing quartiles of mortality risk (very low risk, low risk, moderate risk, high risk). The BARC index was compared to the
established index scores body mass index, obstructive, dyspnoea and exacerbations (BODEx), dyspnoea, obstruction,
smoking and exacerbations (DOSE) and age, dyspnoea and obstruction (ADO).
Results: Fifty-four thousand nine hundred ninety patients were eligible from the first cohort and 4931 from the second
cohort. Eighteen variables were included in the BARC, including age, airflow obstruction, body mass index, smoking,
exacerbations and comorbidities. The risk model had acceptable predictive performance (test set: C-index = 0.79, 95% CI 0.
78–0.81, D-statistic = 1.87, 95% CI 1.77–1.96, calibration slope = 0.95, 95% CI 0.9–0.99; external dataset: C-index = 0.67, 95%
CI 0.65–0.7, D-statistic = 0.98, 95% CI 0.8–1.2, calibration slope = 0.54, 95% CI 0.45–0.64) and acceptable accuracy predicting
the probability of death (probability of death in 1 year, n high-risk group, test set: expected = 0.31, observed = 0.30;
external dataset: expected = 0.22, observed = 0.27). The BARC compared favourably to existing index scores that can also
be applied without specialist respiratory variables (area under the curve: BARC = 0.78, 95% CI 0.76–0.79; BODEx = 0.48, 95%
CI 0.45–0.51; DOSE = 0.60, 95% CI 0.57–0.61; ADO= 0.68, 95% CI 0.66–0.69, external dataset: BARC = 0.70, 95% CI 0.67–0.72;
BODEx = 0.41, 95% CI 0.38–0.45; DOSE = 0.52, 95% CI 0.49–0.55; ADO= 0.57, 95% CI 0.54–0.60).
Conclusion: The BARC index performed better than existing tools in predicting 1-year mortality. Critically, the risk score
only requires routinely collected non-specialist information which, therefore, could help identify patients seen in primary
care that may benefit from palliative care.
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Introduction
Chronic obstructive pulmonary disease (COPD) is associ-
ated with significant mortality and morbidity and is one of
the most prevalent chronic diseases globally; in the UK, it
is the fifth highest cause of death [1, 2]. As COPD
progresses, patients experience significant decreases in
functional capacity, quality of life, social ability and psycho-
logical well-being, impairments that are analogous to those
from lung cancer. There is growing evidence and increasing
expert opinion that palliative care should have a prominent
role in patients with end-stage COPD [3, 4]. UK clinical
guidelines (National Health Service, National Institute for
Health and Care Excellence, National Council for Palliative
Care) all recommend starting palliative care in the year
before people die, with the goal of both improving their
quality of life and addressing end-of-life planning [3, 5].
The healthcare workers best placed to enable this are often
those in primary care. However, we have previously shown
in the UK that only 1 in 5 COPD patients within the last
year of life are provided palliative care, and a recent Canad-
ian study of COPD patients with advanced disease found a
similarly low proportion [6, 7]. One major barrier to
provision is the challenge of predicting patient survival, due
to the irregular disease trajectory of COPD, which is usually
one of slow decline, punctuated by sudden unpredictable
exacerbations that often end in death [4, 8–10]. This is in
contrast to lung cancer, where there is often a reasonable
level of physical function until a short period of relatively
predictable decline. This may partly explain why COPD
patients are much less likely to receive palliative care than
patients with lung cancer [7].
Many derived prognostic indices can help long-term
mortality prediction in COPD, but the ability to predict
death at 12months is currently limited, thought in part to
be because the original derivation of some of the scores
was to predict mortality over several years, as well as the
lack of inclusion of important prognostic factors, such as
comorbidities [4, 8, 11]. Furthermore, these risk scores have
been derived using subgroups of patients, in particular pa-
tients from secondary care, where more specialised test re-
sults are available. Hence, these indices often cannot be
applied to the general COPD population, for example, the
BODE index is the most commonly used yet requires
knowledge of a patient’s exercise capacity, measured by
their 6-min walk test, which is not routinely carried out in
a primary care setting. This limitation prevents those that
most commonly attend to COPD patients, healthcare
workers within primary care, from identifying COPD pa-
tients that would benefit from palliative care. Lastly, the
simplicity of the most commonly used predictive indexes
may impede their predictive ability, such that addition of
clinical variables increased their performance [11]. This
seems especially relevant when adding comorbidities as
putative prognostic predictors; comorbidities such as
cardiovascular disease, cerebrovascular disease and lung
cancer are both associated with an increased mortality and
are highly prevalent in COPD patients. Moreover, there is
evidence to suggest COPD patients are more likely to die
from their comorbidities than the disease itself [12].
The aim of this study was to devise a prognostic tool,
based on routinely collected variables within primary care,
which could provide a 12-month mortality prognosis for
general COPD patients. To carry this out, we used the
UK’s largest longitudinal database of electronic healthcare
records and incorporated in our analysis all recorded pu-
tative predictive risk factors; these risk factors were based
on previous published indices and risk scores.
Methods
Data sources
Data from the Clinical Practice Research Datalink (CPRD)
was used to derive the prognostic risk model. CPRD cur-
rently covers more than 11 million patients, who represent
the population, including with respect to gender and age,
containing primary care clinical, prescription and test data
[13]. To obtain data on exacerbations, socioeconomic sta-
tus and mortality, linkage respectively to Hospital Episode
Statistics (HES), Index of Multiple Deprivation (IMD) and
Office of National Statistics (ONS) data was obtained; just
over 60% of CPRD practices have patient-level linkage to
HES-IMD-ONS.
Study populations
All patients had a COPD diagnosis as determined using a
previously validated algorithm [14]. Patients’ data were eli-
gible for inclusion after the latest of their COPD diagnosis
date, the date the GP practice began recording research
quality data, their continuous CPRD registration date, or
cohort start date. Patients’ data were censored at the earli-
est of their date of death, end of study (26 June 2015), the
GP practice last collection date or the date of transfer out
of a CPRD-linked practice. Two study populations were
drawn. The first had a cohort start date of 1 January 2010,
and an arbitrary index date (time from which the 1-year
mortality prognosis model could be applied) set as the first
annual COPD review that occurred 12 months after
eligibility. This cohort was used to derive the model and
internally validate the model.
A second population was drawn that did not have a
recorded annual review date and had data drawn from
an earlier time period. The second cohort start date was
1 January 2004, and index date was arbitrarily set as the
first day after 12 months of eligible data had occurred.
Patients were excluded if they had a recorded annual
review date between 1 January 2004 and 26 June 2015,
and if they had missing values required for the model.
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Outcome and prognostic predictors
Death was defined as mortality from any cause. The
following prognostic predictors were chosen, based on pub-
lished indices and risk scores, using appropriate Read codes
(codes are available upon request): history of smoking
(current or ex-smoker), MRC dyspnoea score, bereavement,
myocardial infarction, asthma, osteoporosis, diabetes,
hypertension, dementia, lung cancer, heart failure, stroke,
anxiety, depression, atrial fibrillation, pulmonary embolism,
coronary artery disease, gastric/duodenal ulcer disease,
breast cancer, pancreatic cancer, pulmonary fibrosis, stroke,
long-term oxygen therapy, influenza and pneumococcal
vaccinations (this can be given every 5 years; if records did
not extend beyond 5 years and did not show vaccination,
this was recorded as missing) [8]. The COTE score (based
on the presence of multiple comorbidities, including lung
fibrosis, pancreatic cancer and diabetes with neuropathy)
was also calculated [15]. Lung fibrosis was defined as any
interstitial lung disease (ILD), e.g. sarcoidosis, idiopathic
pulmonary fibrosis, rheumatoid arthritis-associated ILD.
Prescription data was used to identify patients that had ever
used an inhaled corticosteroid (ICS), long-acting beta agon-
ist (LABA), or long-acting muscarinic antagonist (LAMA).
Test results were used to identify the following variables,
FEV1, GOLD staging (FEV1 and FVC), C-reactive protein
(CRP), albumin (low = < 35 g/L), haemoglobin, fibrinogen,
platelets (low = < 150 × 109/L, high = > 400 × 109/L) and
creatinine; creatinine above 120 μmol/L for males, or
110 μmol/L for females, was used to define chronic kidney
disease (CKD). BMI was measured as kg/m2 (underweight
< 19, normal = 19–25, overweight = 25–30, obese ≥ 30). Ex-
acerbations, treated within primary (labelled as moderate)
or secondary care (labelled as severe), were identified using
a validated algorithm [16, 17]. Severe exacerbations were
categorised as none, 1–2 hospitalisations annually and ≥ 3
hospitalisations annually. The rules for variable inclusion
are defined in Additional file 1: Table S1.
Multivariable prognostic scores
Only three of the nine multivariable scores, which have pre-
viously been used to address mortality in unselected COPD
patients at 1 year, were able to be derived from routinely
collected primary care data. These were ADO (age,
dyspnoea and airflow obstruction), BODEx (BMI, airflow
obstruction, dyspnoea and exacerbations) and DOSE (dys-
pnoea, airflow obstruction, smoking status and exacerba-
tions). The scores were derived as per original publication,
using variables as defined above (MRC dyspnoea score,
FEV1, smoking status, exacerbations, BMI) [18–20].
Modelling the putative prognostic predictors
The dataset was randomly divided equally into two data-
sets: a training set, used to derive the model, and a test
set, used to internally validate the risk model.
Variables exceeding 50% missing were excluded from
the model. An imputation model was defined for each
variable with ≤ 50% missing data. Data were assumed to
be missing at random, and values for the missing predic-
tors were imputed using multiple imputation techniques
based on chained equations [21]. A total of 10 imputed
datasets were generated.
To derive the risk model, Cox regression models were
fitted using the data from the training set with all
predictors (with the exclusion of the COTE scores).
Backwards elimination with a stack approach [21] was
used, using a 5% significance level for variable selection
and weights equal to 1/10 for each one of the imputed
training datasets. The coefficient estimates for the final
model were combined from the imputed datasets using
Rubin’s rules [22]. Proportional hazard assumptions were
tested for the final model.
The probability of mortality at 1 year for a patient can
be calculated using the following equation, derived from
the Cox proportional hazards model:
P death at 1 yearð Þ ¼ 1− S0 tð Þð Þ exp prognostic indexð Þ;
where S0(t) is the baseline survival probability at time t
(i.e. at 1 year in this study). The prognostic index, i.e. the
linear predictor of the Cox model, is the quantity we
used as our proposed index. The index was given the
acronym BARC based on putative prognostic factors in-
cluding body mass index and blood results (B), age (A),
respiratory variables (airflow obstruction, exacerbations,
smoking) (R) and comorbidities (C).
Validation of the risk model
To validate the predictive ability of the risk model at
12 months, we relied on the calculation of the BARC
index in the test set using the coefficients obtained in
the development phase. The model was validated intern-
ally in the test dataset and in the external dataset (drawn
from the second COPD cohort). Measures assessing cali-
bration (calibration slope) and discrimination (Harrel’s
C-index and D-statistic) were calculated [23–25]. Cali-
bration slope assesses the agreement between predicted
and observed risks. A calibration slope of 1 suggests per-
fect calibration, while a value diverging from 1 is indica-
tive of poorer agreement. A value of 0.5 for C-index
indicates no discrimination, and 1 indicates perfect dis-
crimination. A model with no discriminatory ability will
produce D value equal to 0, and better separation is
achieved with higher values. The performance measures
were estimated in each imputed validation test dataset,
overall measures were calculated by combining the esti-
mates using Rubin’s rules, and in the external dataset.
Graphical illustration of calibration is given by com-
paring observed (Kaplan–Meier) and predicted survival
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probabilities in several prognostic groups. Groups were
derived by placing cut points on the BARC based on
meaningful quantiles [26, 27]. We categorised BARC
index’s at the 1st quartile, median and 3rd quartile of
the time of death, i.e. not counting censored observa-
tions, to create four risk groups.
Comparing observed and predicted mortality probability
The observed mortality probability was calculated by the
proportion of deceased patients in the sample within a
year. The same four groups used to graphically calibrate
the model were used to classify subjects in very low, low,
moderate and high risk [28]. Mortality could then be com-
pared for patients in each risk group between that ob-
served and the predicted mortality using the BARC index.
Comparing the risk model with established multivariable
prognostic scores
To compare the predictive capability of the BARC index
with that of ADO, BODEx and DOSE scores, we plotted
the receiver operating characteristic (ROC) curves and
calculated their associated area under the curves (AUC)
for the survival threshold of interest, i.e. 1 year. As a sen-
sitivity analysis, the scores were compared on the first
cohort (training and test set) without lung cancer.
All statistical analyses were carried out using STATA
(version 15) and R (version 3.5.0).
Results
Characteristics of the COPD populations
There were 54,990 eligible COPD patients in the first
cohort, from which the training and test datasets were
drawn, of whom 21% died during study follow-up;
median follow-up was 2.7 years (Additional file 1). The
cohort had a median age of 70 years, around half were
male, median BMI corresponding to overweight and a
median FEV1 of 1.48 L (Table 1). All of the cohort had a
history of at least one documented comorbidity. Only
1.2% of the cohort had a high COTE index. As might be
expected, the cohort that died were slightly older, had a
lower FEV1, had experienced more moderate and severe
exacerbations, were on more inhaled medication and
had in general more comorbidities. There were 4931
eligible COPD patients in the external validation dataset
(Additional file 2: Figure S1), drawn from the second
COPD cohort of whom 29% died during study
follow-up; median follow-up was 2.1 years. The dataset
had a median age of 71 years, 55% were males, and a
median FEV1 was 1.52 L (Table 2). The patients that died
were older, had a lower FEV1 and had more exacerba-
tions and comorbidities.
Prevalence of prognostic predictors
In the first primary care COPD cohort, there was < 5%
missing data for the most commonly applied prognostic
predictors, MRC dyspnoea score, BMI, smoking status,
exacerbation history and age, except for FEV1 where
there was 20% missing. Other predictors that had miss-
ing values were blood tests; CRP had 79% missing, albu-
min, haemoglobin, and platelets had around 30%
missing and creatinine only had 23% missing. Only 16%
of patients did not have a blood test within 12 months of
their annual review, and only 3% were taken within 7
days either side of an exacerbation. There was 70% of
patients with missing data for the pneumococcal vaccine.
All other variables, unless derived from the abovemen-
tioned variables, were < 5% missing.
Identification of the risk model
After imputation for the missing values and stepwise
elimination, 18 different variables remained in the
model, including age, BMI, FEV1, severe exacerbations,
smoking status, multiple comorbidities, haemoglobin
and platelets (Table 3).
The marginal predictions for the risk of death at 1 year
were obtained by the following equation
P death at 1 yearð Þ ¼ 1− 0:9837ð Þ exp prognostic indexð Þ;
where the baseline survival is estimated by means of a
fractional polynomial and the prognostic index is the lin-
ear combination of the coefficients given in Table 3 with
the values of the corresponding variables.
Validation of the risk model
The predictive performance and calibration of the BARC
index was high in the test dataset and satisfactory in the
external dataset (test set: C-index 0.79, 95% CI 0.78–0.81;
D-statistic 1.9, 95% CI 1.8–2.0; calibration slope 0.95, 95%
CI 0.90–0.99, and external dataset: C-index 0.67, 95% CI
0.65–0.70; D-statistic 0.98, 95% CI 0.83–1.14; calibration
slope 0.54, 95% CI 0.45–0.64) (Table 4). We depict the ob-
served and fitted survival probabilities, with pointwise
95% confidence intervals for the latter, at 3, 6 and 9
months, other than at 1 year, to give a visual trend of the
survival probabilities. The graphical analysis confirms the
satisfactory calibration of the BARC index (Add-
itional file 3: Figure S2), even if the predictions in some of
the groups were slightly higher than the observed.
Comparing mortality between that observed and
predicted
There was an increasing probability of death with each
increasing risk group (Fig. 1). The BARC index esti-
mated the probability of dying to within 1% of the
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Table 1 Demographic and clinical characteristics of the first COPD cohort (training and test datasets)
Characteristic Training set Test set Died Not died
N % N % N % N %
Total 27,472 50.0 27,518 50.0 11,775 21.4 43,215 78.6
Mean age, years (SD) 69.9 (10.7) 70.0 (10.6) 76.6 (9.2) 68.1 (10.3)
Gender (males) 14,869 54.1 12,603 45.9 4933 41.9 20,353 47.1
IMD quartiles
1 (least deprived) 5251 19.2 5254 19.1 2237 19.0 8268 19.1
2 6926 25.3 6910 25.2 3021 25.7 10,815 25.0
3 7314 26.7 7341 26.8 3176 27.0 11,479 26.6
4 7891 28.8 7937 28.9 3327 28.3 12,501 28.9
Mean BMI, kg/m2 (SD) 27.5 (6.2) 27.5 (6.2) 26.0 (6.3) 28.0 (6.1)
Mean FEV1, L (SD) 1.59 (0.7) 1.59 (0.7) 1.27 (0.60) 1.67 (0.69)
GOLD stage
1 10,117 43.1 10,231 43.5 3205 27.2 17,143 39.7
2 7850 33.5 7883 33.5 2776 23.6 12,957 30.0
3 4459 19.0 4407 18.8 2545 21.6 6321 14.6
4 1031 4.4 987 4.2 886 7.5 1132 2.6
MRC score
1 14,553 53.5 14,524 53.5 3793 32.2 25,284 58.5
2 7011 25.8 7025 25.9 3262 27.7 10,774 24.9
3 4497 16.5 4482 16.5 3185 27.0 5794 13.4
4 1144 4.2 1118 4.1 1349 11.5 913 2.1
Smoking status
Current 16,006 58.2 15,829 57.6 7272 61.8 24,563 56.8
Ex-smoker 11,512 41.8 11,643 42.4 4503 38.2 18,652 43.2
GP treated exacerbations
1–2 7885 28.7 7738 28.2 3483 29.6 12,140 28.1
> 2 2230 8.1 2272 8.3 1291 11.0 3211 7.4
Hospitalised exacerbations
1–2 1548 5.6 1609 5.9 1399 11.9 1758 4.1
> 2 149 0.5 118 0.4 181 1.5 86 0.2
Medications
ICS 19,252 70.0 18,932 68.9 8937 75.9 29,247 67.7
LABA 17,638 64.1 17,456 63.5 8330 70.7 26,764 61.9
LAMA 13,522 49.1 13,585 49.5 6636 56.4 20,471 47.4
Influenza vaccination 22,663 82.4 22,649 82.4 9984 84.8 35,328 81.7
Pneumococcal vaccination 2195 27.5 1983 25.5 1059 9.0 3119 7.2
Comorbidities
Myocardial infarction 2310 8.4 2162 7.8 1501 12.8 2971 6.7
Stroke 1393 5.1 1387 5.1 947 8.0 1833 15.6
Asthma 13,442 48.9 13,198 48.0 5937 50.4 20,703 175.8
Hypertension 13,263 48.3 13,130 47.7 6550 55.6 19,843 168.5
Atrial fibrillation (COTE) 2157 7.9 2222 8.1 1176 10.0 2663 22.6
Chronic kidney disease 2403 8.7 2391 8.7 2805 23.8 1989 16.9
Dementia 428 1.6 418 1.5 424 3.6 422 3.6
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observed probability in the high-risk group, in the train-
ing and test sets, and within 5% in the external dataset.
Comparing the BARC to ADO, BODEx and DOSE
The ROC curve of the BARC index was consistently
above any of the curves associated with both ADO,
BODEx and DOSE scores, showing that our model per-
formed better in the test dataset than the three scores
(Fig. 2 and Additional file 4: Figure S3). This result is
confirmed by the associated AUCs and their correspond-
ing 95% confidence intervals (Table 5). BARC index still
performed better in the sensitivity analysis, removing
lung cancer patients (Additional file 1: Tables S2-S4).
Discussion
From a large cohort of primary care COPD patients, we
have derived a 12-month mortality predictive model, the
BARC index, with acceptable discrimination and calibra-
tion when externally validated. The predictive performance
of the model also compared favourably to the commonly
used ADO, DOSE and BODEx indexes. The BARC index
is comprised of variables commonly included in established
predictive indexes, such as airway obstruction, age, smok-
ing status and dyspnoea assessment, as well as several co-
morbidities and blood biomarkers linked to general health
(including serum albumin and haemoglobin).
A significant difference between our more favourable
model and established scores is the addition of comor-
bidities. The presence of comorbid disease is common,
with at least 80% of COPD patients estimated to have
one or more additional chronic disorders; indeed, those
within 1 year of death have an even larger proportion
with comorbid disease [7, 29]. It is also associated with
significantly increased mortality; up to two thirds of
deaths are thought to be from comorbid disease not
COPD [12, 15, 30]. Perhaps unexpectedly, most cardio-
vascular comorbidities were not included in the model
at the 5% significance level; however, this may be be-
cause this model addressed shorter-term 12-month mor-
tality whereas cardiovascular disease has relatively
longer-term effects, than some other comorbidities, such
as cirrhosis, lung cancer and cerebrovascular disease that
were included. Furthermore, cardiovascular mortality
continues to decrease [31]. The specific comorbidities
Table 1 Demographic and clinical characteristics of the first COPD cohort (training and test datasets) (Continued)
Characteristic Training set Test set Died Not died
N % N % N % N %
Anxiety (COTE) 6689 24.3 6715 24.4 2729 23.2 10,675 90.7
Depression 7941 28.9 8027 29.2 3004 25.5 12,964 110.1
Lung cancer (COTE) 1109 4.0 1055 3.8 1282 10.9 882 7.5
Cirrhosis (COTE) 119 0.4 118 0.4 76 0.6 161 1.4
Oesophageal cancer (COTE) 41 0.1 35 0.1 41 0.3 35 0.3
Diabetes 4599 16.7 4742 17.2 2408 20.5 6933 58.9
Pulmonary embolism 642 2.3 680 2.5 374 3.2 948 8.1
Heart failure (COTE) 1825 6.6 1775 6.5 1566 13.3 2034 17.3
Osteoporosis 2421 8.8 2392 8.7 11,480 97.5 3333 28.3
Coronary artery disease (COTE) 5620 20.5 5469 19.9 3361 28.5 7728 65.6
Pancreatic cancer (COTE) 5 0.0 5 0.0 < 5 < 0.1 6 0.1
Pulmonary fibrosis (COTE) 183 0.7 177 0.6 144 1.2 216 1.8
Breast cancer (COTE) 425 1.5 443 1.6 213 1.8 655 5.6
Gastric/duodenal ulcers (COTE) 230 0.8 229 0.8 121 1.0 338 2.9
Diabetes with neuropathy (COTE) 3894 14.2 4021 14.6 2073 17.6 5842 49.6
Blood tests
CRP, mg/L mean (SD) 13.5 (29.5) 13.2 (29.6) 19.4 (36.8) 11.5 (24.5)
Low albumin, g/L 1185 4.3 1176 4.3 1039 8.8 1322 11.2
Hb, g/dL mean (SD) 138.5 (41.4) 138.3 (37.5) 133.7 (40.0) 139.8 (39.2)
Low platelets, × 109/L 655 3.6 690 3.8 431 3.7 914 7.8
High platelets, × 109/L 1374 7.5 1368 7.5 783 6.6 1959 16.6
Creatinine, μmol/L mean (SD) 88.9 (37.7) 88.2 (34.1) 98.1 (48.5) 85.7 (30.6)
Bereavement 1337 4.9 1354 4.9 611 5.2 2080 17.7
Hb haemoglobin. Comorbidities included in COTE are indicated
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index (COTE) uses 12 comorbidities, but no respiratory
parameters, and provides a good 5-year mortality predic-
tion [15]. However, COTE has not been assessed for pre-
dicting mortality at 1 year, and as it was derived in
secondary care, it requires specialised knowledge on dis-
ease status that is not always available. In this respect,
the CODEX index (based on the Charlson index and
BODEx), derived from a selective cohort of hospitalised
COPD patients, also requires in-depth knowledge on co-
morbidities [18]. In comparison, many variables that are
associated with COPD severity, including medication
use, moderate exacerbations and GOLD staging, were
not included in the model at the 5% significance level.
This information in itself points to the complexity of un-
derstanding COPD mortality and highlights again the in-
fluence of comorbid conditions on mortality.
One advantage of the BARC index is that it is prac-
tical, and user-friendly, as it incorporates routinely col-
lected data easily available within primary care, which
could also allow the risk score to be embedded in the
electronic healthcare records system. In addition,
Table 2 Demographic and clinical characteristics of the external
dataset
Characteristic External set Died Not died
N % N % N %
Total 4931 100 1424 28.9 3507 71.1
Mean age, years (SD) 71.1 (11.0) 75.0 (9.0) 68.3 (11.1)
Gender (males) 2718 55.1 912 64 1806 51.5
Mean BMI, kg/m2 (SD) 26.9 (6.5) 25.2 (6.2) 27.7 (6.4)
Mean FEV1, L (SD) 1.52 (0.70) 1.34 (0.61) 1.73 (0.70)
MRC score
1 2433 49.3 478 33.6 1955 55.8
2 1224 24.8 373 26.2 851 24.3
3 926 18.8 387 27.2 539 15.4
4 348 7.1 186 13.1 162 4.6
Smoking status
Ex-smoker 2657 53.9 793 55.7 1864 53.1
Current 2274 46.1 631 44.3 1643 46.9
Hospitalised exacerbations
1–2 224 4.5 102 1.2 122 3.5
> 2 9 0.2 7 0.5 < 5 .
Comorbidities
Stroke 368 7.5 144 10.1 224 6.4
Asthma 2452 49.7 736 51.7 1716 48.9
Hypertension
Atrial fibrillation (COTE) 731 14.8 330 23.2 401 11.4
Chronic kidney disease 733 14.9 340 23.9 393 11.2
Dementia 210 4.3 76 5.3 134 3.8
Lung cancer (COTE) 80 1.6 50 3.5 30 0.9
Pulmonary fibrosis (COTE) 80 1.6 33 2.3 47 1.3
Blood tests
Low albumin, g/L 369 7.5 153 10.7 216 6.2
Hb, g/dL mean (SD) 141.1 (67.7) 143.6 (102.0) 140.0 (47.1)
Low platelets, × 109/L 211 4.3 142 4.1 69 4.9
High platelets, × 109/L 398 8.1 138 9.7 260 7.4
Creatinine, μmol/L mean (SD) 94.1 (45.4) 105 (52.5) 89.4 (41.3)
Table 3 Estimated beta coefficients and their standard errors
(SE) for the final Cox proportional hazards model
Coefficient SE p value
Continuous variables
Age 0.040 0.004 < 0.0001
BMI − 0.047 0.006 < 0.0001
Creatinine 0.001 0.001 < 0.05
Haemoglobin − 0.006 0.001 < 0.0001
FEV1 − 0.433 0.078 < 0.0001
Categorical variables
Asthma − 0.155 0.057 < 0.01
Atrial fibrillation 0.450 0.077 < 0.0001
No CKD − 0.314 0.143 < 0.05
Current smoker 0.179 0.061 < 0.05
Dementia 0.391 0.137 < 0.01
Female − 0.331 0.069 < 0.0001
Hospitalisations
1–2/year 0.517 0.081 < 0.0001
> 2/year 0.980 0.181 < 0.0001
Low albumin 0.531 0.089 < 0.0001
Lung cancer 1.063 0.135 < 0.0001
Lung fibrosis 0.794 0.219 < 0.0001
MRC
2 0.577 0.130 < 0.0001
3 0.890 0.133 < 0.0001
4 1.599 0.142 < 0.0001
Platelets
Normal − 0.394 0.131 < 0.01
High − 0.208 0.161 > 0.05
Stroke 0.235 0.097 < 0.05
Table 4 Validation at 12 months using the test and external
validation datasets
Mean SE 95% CI Mean SE 95% CI
Test set External validation
Harrell’s C-index 0.794 0.006 0.782–0.807 0.671 0.012 0.647–0.695
D-statistic 1.865 0.048 1.770–1.959 0.983 0.080 0.826–1.141
Calibration slope 0.947 0.024 0.900–0.993 0.544 0.046 0.454–0.635
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because it was derived and validated in two large nation-
ally representative COPD populations, and nearly 90% of
UK population is registered in primary care, this aids the
generalisability of the risk score to all COPD popula-
tions. The cohorts used had similar mortality rates to
other COPD cohorts (data not shown) [11, 32]. How-
ever, the generalisability could have been reduced as we
used an annual review as the arbitrary time point from
which to start the study; 20% of the cohort did not have
one during their study period, and this was largely due
to their short length of research quality data available
(i.e. only had just over 1 year of CPRD data therefore
not long enough to have 1 year of data and an annual
review) rather than lack of attendance to their annual
Fig. 1 Mortality probability by PI group in training, test and external validation datasets
Fig. 2 Receiver operating curves comparing the BARC index with ADO, BODEx and DOSE indexes
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review. This generalisability issue was overcome as the
external dataset contained patients without an annual
review during that time period. Another possible limita-
tion of the derivation of the risk score is that five
variables (FEV1, albumin, haemoglobin, platelets and
creatinine) had to be imputed due to missing data,
which potentially could have led to misclassification,
though the percentage missing was only around 10 to
30%. The low percentage of missing data in the first
cohort was likely due to some selection bias as these
patients all had an annual review; there was higher per-
centage missing in the second cohort, with 15% missing
FEV1 and 50% missing MRC dyspnoea score. In the first
cohort, many of the missing variables appeared to be
missing due to a relatively short follow-up period before
death (in the UK FEV1 is routinely measured every 18
months); nevertheless, FEV1 can readily be measured by
spirometry if required for the index. Although blood
tests were missing from some patients, these provided
significant predictive value to the model and were
mostly performed less than a year before the annual
review date. Moreover, we feel it is likely in patients
where a GP is considering this index, they will have had
a blood test in the recent past; if not, this information
can easily be obtained from a simple single blood test. A
strength of this study is the use of such a large cohort of
patients to derive the model from; this also provided the
power to assess less-common comorbidities (including
cirrhosis and dementia) as statistically significant
prognostic markers that may not have been found in a
smaller sample size.
Information on the end of life has been identified as of
intrinsic interest to patients, carers and healthcare pro-
fessionals, but the lack of the ability to approximately
predict mortality is thought to be one of the key barriers
to providing this information. Therefore, the identifica-
tion of this accurate, user-friendly, predictive model that
is applicable in primary care, could aid communication,
shared decision-making and ultimately a palliative care
approach directed from primary care. Our findings
suggest the currently used predictive scores may be too
simple and that incorporating more clinical variables, in
particular comorbidities, significantly improves predict-
ive performance. Of course, a risk score only aids
decision-making, and physicians should use their clinical
acumen and discuss with patients and their families to
decide when palliative care is appropriate (it may be ap-
propriate long before the last year of life); a risk score
should not be used in isolation as a screening tool for
palliative care [28].
Conclusions
This is the first published prognostic tool designed to pre-
dict all-cause mortality in patients with COPD within 12
months of death. In addition, its applicability in primary
care, and validation in a large general COPD cohort, gives
the BARC index significant clinical and practical advan-
tages over previously identified risk indices.
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